期刊文献+

E6-AP对前列腺癌细胞株LNCaP细胞增殖和细胞周期的影响

Effects of E6-AP on proliferation and cell cycle of human prostate cancer LNCaP cells
下载PDF
导出
摘要 目的:研究E6相关蛋白(E6-AP)对前列腺癌细胞增殖和细胞周期的影响,阐明E6-AP在雄激素受体通路中的作用机制及在前列腺癌发生发展中的作用。方法:采用电穿孔方法制备tTA及E6-AP稳定转染细胞株;利用强力霉素(DOX)的调节作用,通过MTT实验观察E6-AP过表达及低表达对LNCaP细胞增殖的影响;利用流式细胞仪进行PI单染色检测E6-AP过表达及低表达对LNCaP细胞周期进程的影响。结果:成功构建双质粒稳定转染细胞株,与E6-AP低表达的LNCaP细胞和DOX关闭表达后的稳定株比较,E6-AP过表达的LNCaP细胞数目明显增多(P<0.01),且处于S期的细胞比例明显增大(P<0.01)。结论:E6-AP过表达可促进LNCaP细胞增殖并促进细胞进入S期,提示E6-AP与雄激素受体信号通路有密切关联。 Objective To investigate the effects of E6-AP on cell proliferation and cell cycle of human prostate cancer cells and elucidate the role of E6-AP participating in androgen receptor signal pathway and in the progress of prostate cancer.Methods tTA and E6-AP overexpression LNCaP cell line was established by electroporation transfection.The cell viability was analyzed by MTT assay and cell cycle distribution was detected by flow cytometry after propidium iodide staining using the stable cell line under the regulation of Dox.Results LNCaP cell line overexpressing E6-AP was established successfully.Compared with untreated LNCaP cell and Dox treated E6-AP stable cell line,the total number and the proportion in S phase of Dox treated E6-AP stable cells were increased significantly(P0.01).Conclusion Overexpression of E6-AP induces proliferation of LNCaP cells and increase the number of cells in S phase,indicating that E6-AP is involved in androgen receptor signal pathway.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2011年第1期64-67,共4页 Journal of Jilin University:Medicine Edition
基金 吉林省卫生厅重点项目资助课题(200599)
关键词 E6相关蛋白 前列腺肿瘤 细胞增殖 细胞周期 E6-associated protein prostatic neoplasms cell proliferation cell cycle
  • 相关文献

参考文献13

  • 1Lubahn DB, Joseph DR, Sar M, et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate [J]. Mol Endocrinol, 1988, 2 (12): 1265- 1275.
  • 2Singh P, Uzgare A, Litvinov I, et al. Combinatorial androgen receptor targeted therapy for prostate cancer[J]. Endoer Relat Cancer, 2006, 13(2):653 -666.
  • 3Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy [J]. Nat Med, 2004, 10(3) : 33-39.
  • 4Heemers HV, Tindall DJ. Androgen receptor ( AR ) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex [J]. Endocr Rev,2007, 28 (7): 778-808.
  • 5Ligr M, Li Y, Zou X, et al. Tumor suppressor function of androgen receptor coactivator ARAT0alpha in prostate cancer[J]. Am J Pathol, 2010, 176(4):1891 -1900.
  • 6McKenna NJ, Lanz RB, O' Malley BW. Nuclear receptor coregulators: cellular and molecular biology[J]. Endoer Rev, 1999, 20(3): 321-334.
  • 7谢棒祥,周建光.雄激素受体共调节因子及其在前列腺癌进展中的作用[J].生物技术通讯,2008,19(5):740-742. 被引量:1
  • 8Agoulnik IU, Weigel NL. Coactivator selective regulation of androgen receptor activity[J]. Steroids, 2009, 74 (8): 669- 674.
  • 9Labrie F. Hormonal therapy of proslate cancer[J]. Prog Brain Res, 2010, 182(6): 321-341.
  • 10Williams C. Angelman syndrome scientific symposium on the structure and function of UBE3A/E6AP[J]. J Child Neurol, 2009, 24(7): 904- 908.

二级参考文献32

  • 1Lin HK, Hu RC, Yang L, et al. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers[J].J Biol Chem, 2003, 278 (10):50902-50907.
  • 2Baek SH, Ohgi KA, Nelson CA, et al. Ligand-specific allosteric regulation of eoactivator functions of androgen receptor in prostate cancer cells [J]. Proc Natl Aead Sei USA, 2006, 103 (9): 3100-3105.
  • 3Lee HJ, Chang C. Recent advances in androgen receptor action [J]. Cell Mol Life Sci, 2003, 60 (8): 1613-1622.
  • 4Liao S. Androgen action: molecular mechanism and medical application [J]. J Formos Med Assoc, 1994, 93 (9): 741- 751.
  • 5Suzuki H, Ueda T, Ichikawa T, et al. Androgen receptor involvement in the progression of prostate cancer [J]. Endocr Relat Cancer, 2003, 10 (2): 209-216.
  • 6Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel , estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer:a final report of CALGB 9780. Cancer and Leukemia Group B[J]. J Clin Oncol, 2001, 19 (9): 2509-2516.
  • 7Heinlein CA, Chang C. Androgen receptor ( AR ) coregulators: an overview[J]. Endocr Rev, 2002, 23 (2): 175-200.
  • 8Heemers HV, Tindall DJ. Androgen receptor ( AR ) coregulators: A diversity of functions converging on and Regulating the AR transcriptional complex [J]. Endocr Rev, 2007, 28 (7): 778-808.
  • 9Nawaz Z, Lonard DM, Smith CL, et ai. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily [J]. Mol Cell Biol, 1999, 19 (2):1182-1189.
  • 10Smith CL, DeVera DG, Lamb DJ, et al. Genetic ablation of the steroid receptor coaetivator-ubiquitin ligase, E6 AP, results in tissue-selective steroid hormone resistance and defects in reproduction [J].Mol Cell Biol, 2002, 22 (2): 525 -535.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部